GAMIDA CELL LTD (GMDA) Stock Price & Overview
NASDAQ:GMDA • IL0011552663
The current stock price of GMDA is 0.0327 USD. Today GMDA is down by -18.25%. In the past month the price decreased by -90.3%. In the past year, price decreased by -95.57%.
GMDA Key Statistics
- Market Cap
- 4.337M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.63
- Dividend Yield
- N/A
GMDA Stock Performance
GMDA Stock Chart
GMDA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to GMDA. When comparing the yearly performance of all stocks, GMDA is a bad performer in the overall market: 99.82% of all stocks are doing better.
GMDA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GMDA. GMDA may be in some trouble as it scores bad on both profitability and health.
GMDA Earnings
GMDA Forecast & Estimates
10 analysts have analysed GMDA and the average price target is 4.42 USD. This implies a price increase of 13416.73% is expected in the next year compared to the current price of 0.0327.
For the next year, analysts expect an EPS growth of 9.37% and a revenue growth 808.75% for GMDA
GMDA Groups
Sector & Classification
GMDA Financial Highlights
Over the last trailing twelve months GMDA reported a non-GAAP Earnings per Share(EPS) of -0.63. The EPS increased by 49.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.65% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GMDA Ownership
GMDA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.8 | 398.492B | ||
| AMGN | AMGEN INC | 16.04 | 198.265B | ||
| GILD | GILEAD SCIENCES INC | 16.4 | 180.267B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.21 | 121.459B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.95 | 78.932B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.01 | 42.071B | ||
| INSM | INSMED INC | N/A | 30.073B | ||
| BIIB | BIOGEN INC | 11.29 | 27.136B | ||
| NTRA | NATERA INC | N/A | 26.973B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.95 | 23.353B | ||
| MRNA | MODERNA INC | N/A | 21.086B | ||
| EXAS | EXACT SCIENCES CORP | 340.74 | 19.713B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.84B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GMDA
Company Profile
Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The firm is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.
Company Info
IPO: 2018-10-26
GAMIDA CELL LTD
PO Box 34670
JERUSALEM 95484 IL
CEO: Julian Adams
Employees: 143
Phone: 97226595666
GAMIDA CELL LTD / GMDA FAQ
Can you describe the business of GAMIDA CELL LTD?
Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The firm is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.
Can you provide the latest stock price for GAMIDA CELL LTD?
The current stock price of GMDA is 0.0327 USD. The price decreased by -18.25% in the last trading session.
What is the dividend status of GAMIDA CELL LTD?
GMDA does not pay a dividend.
What is the ChartMill rating of GAMIDA CELL LTD stock?
GMDA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for GMDA stock?
The Revenue of GAMIDA CELL LTD (GMDA) is expected to grow by 808.75% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for GMDA stock?
GAMIDA CELL LTD (GMDA) currently has 143 employees.